Goodbody Health subsidiary granted Home Office controlled drugs licence

Goodbody Health

Goodbody Health Inc. (AQSE:GDBY) has announced that its subsidiary, PhytoVista Laboratories, has been granted a controlled drugs licence that allows the company to handle up to Schedule 1 Controlled Drugs.  This comes as the UK authorities look to the regulation of the UK consumer cannabinoid product testing infrastructure ahead of wider compliance within the industry.

The FSA have released the list of products associated with a credible Novel Food application and we expect the industry to continue to move to a fully regulated market that the Consumer can trust.

PhytoVista is one of a small number of laboratories accredited by the UK National Accreditation Service (UKAS) with extended provisions to carry out these specialist activities. 

Geremy Thomas, Goodbody Health Executive Chairman, said: “After significant hard work and investment, we are delighted to be recognised and awarded this highly controlled and regulated licence. PhytoVista continues to be a material part of the Government’s commitment to create a compliant, consumer cannabinoid industry.”

You might also enjoy reading  Goodbody Health to de-list from CSE to better align corporate structure
Find more news, interviews, share price & company profile here for:
Goodbody Health

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit
Find more news, interviews, share price & company profile here for:
Goodbody Health

AIM All Share Index